"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at standard treatment with or without paclitaxel for ovarian cancer that has come back (ICON 4)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared standard treatment alone using ‘platinum’ chemotherapy such as carboplatin or cisplatin with standard treatment and paclitaxel (Taxol) for ovarian cancer. It recruited women whose cancer had come back (recurred) after treatment.
More about this trial
Doctors usually treat ovarian cancer with surgery and chemotherapy. But sometimes ovarian cancer starts to grow again after it is first treated. If this happens, it can be more difficult to treat successfully.
The aims of this trial were to find out
- If standard treatment and paclitaxel is better than standard treatment alone for ovarian cancer that has come back
- More about the side effects and quality of life
Summary of results
The trial team found that standard treatment together with paclitaxel is a useful treatment for ovarian cancer that has come back after it was first treated.
The trial recruited 802 women with ovarian cancer that had come back at least 6 months after first chemotherapy treatment.
- Half had standard treatment with ‘platinum’ chemotherapy such as carboplatin or cisplatin
- Half had standard treatment and paclitaxel
The researchers analysed the results in 2003. They found the cancer went away or shrank in more women who had paclitaxel with standard treatment than in women who had standard treatment alone.
They also found that more women lived for longer than 2 years after treatment in the paclitaxel group (57%) than in the group who had standard treatment alone (50%).
Women in the paclitaxel group had more hair loss and problems with numbness or tingling in their hands or feet (peripheral neuropathy). But fewer problems with a drop in blood counts than the women in the standard treatment group. Overall, the researchers found no difference in quality of life between the 2 different treatment groups.
The researchers concluded that women whose ovarian cancer comes back more than 6 months after first treatment could benefit from further standard treatment and paclitaxel. This applies even if they had paclitaxel as part of their first treatment.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Prof Jonathan Ledermann
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer